Home / Business and Economy / Ozempic Maker Settles Lawsuit With Hims & Hers
Ozempic Maker Settles Lawsuit With Hims & Hers
10 Mar
Summary
- Novo Nordisk to sell Ozempic and Wegovy via Hims & Hers.
- Partnership resolves lawsuit over compounded GLP-1 drugs.
- Hims will now offer FDA-approved injectables at Novo's prices.
Novo Nordisk announced on Monday a new partnership with Hims & Hers, allowing the telehealth company to sell the blockbuster drugs Ozempic and Wegovy. This agreement concludes a legal battle that began when Novo Nordisk sued Hims in February over compounded versions of its GLP-1 medications.
Hims will now offer FDA-approved Ozempic and Wegovy injectables, along with the Wegovy pill, on its platform. These will be sold at Novo's self-pay prices, making them competitive with compounded alternatives. The company stated that compounded GLP-1 drugs will continue to be offered only when deemed clinically necessary by providers, aligning with FDA regulations.
This resolution follows regulatory scrutiny from the FDA, which had also planned action against Hims for marketing unauthorized drugs. The partnership aims to provide consumers with affordable access to authentic GLP-1 treatments. Novo Nordisk CEO Mike Doustdar noted that telehealth partnerships are accelerating drug uptake, with the Wegovy pill alone generating over 600,000 prescriptions since its launch two months prior.
Novo Nordisk had previously cut prices for its weight-loss drugs to compete more effectively in the market. The agreement sees Novo Nordisk withdrawing its patent infringement lawsuit against Hims, reserving the right to refile if necessary. Hims CEO Andrew Dudum expressed optimism about growth through branded, FDA-approved treatments.
